{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:51:17Z","timestamp":1793998277503,"version":"4.8.0"},"reference-count":80,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2340932","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T03:03:48Z","timestamp":1712631828000},"page":"627-643","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4570-9972","authenticated-orcid":false,"given":"Karissa","family":"Johnston","sequence":"first","affiliation":[{"name":"Broadstreet Health Economics and Outcomes Research","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4329-5166","authenticated-orcid":false,"given":"Lauren C.","family":"Powell","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics and Outcomes Research","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-3147","authenticated-orcid":false,"given":"Evan","family":"Popoff","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics and Outcomes Research","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil J.","family":"L\u2019Italien","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0769-6219","authenticated-orcid":false,"given":"Robert","family":"Pawinski","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-6237","authenticated-orcid":false,"given":"Aideen","family":"Ahern","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9628-1922","authenticated-orcid":false,"given":"Sam","family":"Large","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7007-3661","authenticated-orcid":false,"given":"Thang","family":"Tran","sequence":"additional","affiliation":[{"name":"Pfizer Canada","place":["Kirkland, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-9388","authenticated-orcid":false,"given":"Aaron","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"issue":"4","key":"e_1_3_4_3_1","first-page":"243","article-title":"Acute migraine headache: treatment strategies","volume":"97","author":"Mayans L","year":"2018","unstructured":"Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97(4):243\u2013251.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002275"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_3_4_8_1","first-page":"9","article-title":"One-year incidence of migraine in the US population: results from the migraine in America symptoms and treatment (MAST) study (abstract OR08)","volume":"59","author":"Lipton RB","year":"2019","unstructured":"Lipton RB, Rm, Munjal S. One-year incidence of migraine in the US population: results from the migraine in America symptoms and treatment (MAST) study (abstract OR08). Headache. 2019;59:9\u201310.","journal-title":"Headache"},{"key":"e_1_3_4_9_1","volume-title":"Improved NHS migraine care to save thousands of hospital stays","author":"National Health Service","year":"2020","unstructured":"National Health Service. Improved NHS migraine care to save thousands of hospital stays. London: NHS; 2020 [cited April\u00a02022]. https:\/\/www.england.nhs.uk\/2020\/01\/improved-nhs-migraine-care\/"},{"key":"e_1_3_4_10_1","unstructured":"The Work Foundation. Society\u2019s headache: The socioeconomic impact of migraine: The Work Foundation; 2018 [cited April 2022]. https:\/\/www.lancaster.ac.uk\/media\/lancaster-university\/content-assets\/documents\/lums\/work-foundation\/SocietysHeadacheTheSocioeconomicimpactofmigraine.pdf."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.2.197"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12820"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.12.020"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00223-y"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01110-9"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420915167"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0964-5"},{"key":"e_1_3_4_19_1","unstructured":"British Association for the Study of Headache. National headache management system for adults. 2019 [2024 Apr 11]. Available from: https:\/\/headache.org.uk\/wp-content\/uploads\/2023\/02\/bash-guideline-2019.pdf"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01781-z"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13179"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12962"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12154"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.59.7.1011"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420966658"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0865-z"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14056"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.93"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.705276"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00748.x"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01111-8"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02451-x"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.6.754"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_3_4_35_1","volume-title":"Headaches in over 12s: diagnosis and management: clinical guideline (CG150)","author":"National Institute for Health and Clinical Excellence","year":"2012","unstructured":"National Institute for Health and Clinical Excellence. Headaches in over 12s: diagnosis and management: clinical guideline (CG150). Manchester: NICE; 2012 [cited May 2021]. https:\/\/www.nice.org.uk\/guidance\/cg150\/chapter\/Key-priorities-for-implementation#tensiontype-headache-migraine-and-cluster-headache"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00304-w"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1027-7"},{"key":"e_1_3_4_38_1","unstructured":"European Medicines Agency. Summary of product characteristics: VYDURA 75\u2009mg oral lyophilisate 2023 [cited 2023 Nov 24]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vydura-epar-product-information_en.pdf."},{"key":"e_1_3_4_39_1","unstructured":"National Institute for Health and Care Excellence. Rimegepant for treating migraine (TA919) 2023 [cited 2023 Oct 23]. https:\/\/www.nice.org.uk\/guidance\/TA919."},{"key":"e_1_3_4_40_1","unstructured":"National Institute for Health and Care Excellence. Rimegepant for preventing migraine (TA906). 2023. https:\/\/www.nice.org.uk\/guidance\/TA906."},{"key":"e_1_3_4_41_1","unstructured":"Scottish Medicines Consortium. Rimegepant (Vydrua\u00ae) is accepted for restricted use within NHS Scotland. 2023 [cited 2023 Nov 23]. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/rimegepant-vydura-resub-smc2603\/."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221141686"},{"issue":"1","key":"e_1_3_4_43_1","first-page":"1","article-title":"Long-term, open-label safety study of rimegepant 75\u2009mg for the treatment of migraine (study 201): interim analysis of safety and exploratory efficacy (poster P235LB)","volume":"59","author":"Lipton RB","year":"2019","unstructured":"Lipton RB, Berman G, Kudrow D, et\u00a0al. Long-term, open-label safety study of rimegepant 75\u2009mg for the treatment of migraine (study 201): interim analysis of safety and exploratory efficacy (poster P235LB). Headache. 2019;59(S1):1\u2013208.","journal-title":"Headache"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158163221075596"},{"key":"e_1_3_4_45_1","unstructured":"Atlas S Touchette D Agboola F et\u00a0al. Acute treatments for migraine: effectiveness and value. 2020 [cited 2022 Jan 18]. http:\/\/icer-review.org\/material\/acute-migraine-evidence-report\/."},{"key":"e_1_3_4_46_1","unstructured":"Biohaven Pharmaceuticals Inc. Data on file: clinical study report BHV3000-303: a Phase 3 Double-blind Randomized Placebo-controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine. 2019."},{"key":"e_1_3_4_47_1","volume-title":"Guide to the methods of technology appraisal 2013","author":"National Institute for Health and Clinical Excellence","year":"2013","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. Manchester: NICE; 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.908"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/2514183X18823377"},{"key":"e_1_3_4_50_1","volume-title":"Erenumab for preventing migraine: Technology appraisal guidance (TA682)","author":"National Institute for Health and Clinical Excellence","year":"2021","unstructured":"National Institute for Health and Clinical Excellence. Erenumab for preventing migraine: Technology appraisal guidance (TA682). Manchester: NICE; 2021 [cited Apr 2022]. https:\/\/www.nice.org.uk\/guidance\/ta682\/resources\/erenumab-for-preventing-migraine-pdf-82609376694469."},{"key":"e_1_3_4_51_1","volume-title":"Fremanezumab for preventing migraine technology appraisal guidance (TA764)","author":"National Institute for Health and Clinical Excellence","year":"2022","unstructured":"National Institute for Health and Clinical Excellence. Fremanezumab for preventing migraine technology appraisal guidance (TA764). Manchester: NICE; 2022 [cited Apr 2022]. https:\/\/www.nice.org.uk\/guidance\/ta764"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"e_1_3_4_54_1","unstructured":"Office for National Statistics. National life tables United Kingdom 2018-2020. 2021 [cited 2022 Jan 2022]. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2018to2020."},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(16)30293-9"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.11.027"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13411"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_3_4_61_1","unstructured":"National Institute for Health and Care Excellence. Committee papers \u2013 Rimegepant for treating acute migraine [ID1539]. 2023 [cited 2023 Oct 23]. https:\/\/www.nice.org.uk\/guidance\/ta919\/documents\/committee-papers-3."},{"key":"e_1_3_4_62_1","volume-title":"Interim results of a long-term safety study of 75\u2009mg rimegepant administered as needed in acute treatment of migraine among Chinese adults","author":"Yu S","year":"2023","unstructured":"Yu S, Ma L, Zhong Q, et\u00a0al. Interim results of a long-term safety study of 75\u2009mg rimegepant administered as needed in acute treatment of migraine among Chinese adults. Seoul, Republic of Korea: International Headache Congress; 2023."},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.12.007"},{"key":"e_1_3_4_64_1","unstructured":"National Institute for Health and Clinical Excellence. Galcanezumab for preventing migraine: Technology appraisal guidance (TA659). Manchester: NICE; 2020 [cited April 2022]. https:\/\/www.nice.org.uk\/guidance\/ta659."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-65"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0907-6"},{"key":"e_1_3_4_67_1","unstructured":"British National Formulary. Drug acquisition cost for rimegepant 8-pack. 2022 [cited 2022 May 1]. https:\/\/bnf.nice.org.uk\/drug\/."},{"issue":"1","key":"e_1_3_4_68_1","first-page":"175","article-title":"Long-term, open-label safety study of rimegepant 75\u2009mg for the treatment of migraine (study 201): interim analysis of safety and exploratory efficacy (abstract P235LB)","volume":"59","author":"Lipton R","year":"2019","unstructured":"Lipton R, Berman G, Kudrow D, et\u00a0al. Long-term, open-label safety study of rimegepant 75\u2009mg for the treatment of migraine (study 201): interim analysis of safety and exploratory efficacy (abstract P235LB). Headache. 2019;59(S1):175.","journal-title":"Headache"},{"key":"e_1_3_4_69_1","unstructured":"Jones K Burns A. Unit costs of health and social care Canterbury (kent). Personal Social Services Research Unit University of Kent; 2021. https:\/\/kar.kent.ac.uk\/92342\/"},{"key":"e_1_3_4_70_1","unstructured":"NHS Improvement. National schedule of NHS costs \u2013 Year 2019\u20132020. 2022. https:\/\/www.england.nhs.uk\/national-cost-collection\/."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411415879"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01378-5"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01467-z"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01429-5"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9783-5"},{"key":"e_1_3_4_76_1","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond MF","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et\u00a0al. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2015."},{"key":"e_1_3_4_77_1","unstructured":"Biohaven Pharmaceuticals Inc. Data on File: clinical study report BHV3000-201: a multicenter open-label long-term safety study of BHV-3000 in the acute treatment of migraine. 2020."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.3698"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01502-z"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0899-2"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01293-9"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2340932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:44:14Z","timestamp":1772779454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2340932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2340932"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2340932","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}